Using TATI and CA 125 to Diagnose Mucinous Ovarian Tumours
Author Information
Author(s): O. Mogensen, B. Mogensen, A. Jakobsen
Primary Institution: Aarhus University Hospital
Hypothesis
Can TATI and CA 125 be used separately and in combination as reliable diagnostic tools for mucinous ovarian tumours?
Conclusion
TATI is a more reliable tumour marker than CA 125 for distinguishing malignant and borderline mucinous ovarian tumours from benign ones.
Supporting Evidence
- TATI was elevated in 83% of malignant and borderline tumours.
- CA 125 was elevated in 50% of malignant and borderline tumours.
- The combined use of TATI and CA 125 ensured diagnosis of all malignant and borderline tumours.
- TATI was increased in only 6% of benign tumours.
Takeaway
Doctors measured two markers, TATI and CA 125, in patients with ovarian tumours to see if they could help tell if the tumours were cancerous. TATI worked better than CA 125.
Methodology
TATI and CA 125 were measured in serum samples from 30 patients with mucinous ovarian tumours before or during surgery.
Limitations
The study was performed on a small series of patients, which may limit the generalizability of the results.
Participant Demographics
30 patients with mucinous ovarian tumours (10 malignant, 2 borderline, 18 benign).
Want to read the original?
Access the complete publication on the publisher's website